[1] Turner NM, MacRae J, Nowlan ML, et al. Quantifying the incidence and burden of herpes zoster in New Zealand general practice:A retrospective cohort study using a natural language processing software inference algorithm[J].BMJ Open,2018,8(5): e021241. [2] Yanni EA, Ferreira G, Guennec M, et al.Burden of herpes zoster in 16 selected immunocompromised populations in England: A cohort study in the Clinical Practice Research Datalink 2000-2012[J].BMJ Open, 2018, 8(6): e020528. [3] Sun X, Wei Z, Lin H, et al.Incidence and disease burden of herpes zoster in the population aged ≥50 years in China:Data from an integrated health care network[J].J Infect, 2021, 82(2):253-260. [4] Yang F, Yu S, Fan B, et al.The epidemiology of herpes zoster and postherpetic neuralgia in China: Results from a cross-sectional study[J].Pain Ther, 2019, 8(2):249-259. [5] Xing X, Sun K, Yan M.Delayed initiation of supplemental pain management is associated with postherpetic neuralgia: A retrospective study[J].Pain Physician, 2020, 23(1):65-72. [6] Lu L,Suo L,Li J,et al.A retrospective survey on herpes zoster disease burden and characteristics in Beijing,China[J].Hum Vaccin Immunother, 2018, 14(11):2632-2635. [7] Dooling KL, Guo A, Patel M, et al.Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines[J].MMWR Morb Mortal Wkly Rep, 2018, 67(3): 103-108. [8] Choi WS, Choi JH, Jung DS, et al.Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax (R) in healthy adults aged 50 years and older[J].Vaccine, 2019, 37(27):3605-3610. [9] 王官清,李晓霞.带状疱疹的临床流行病学及预防[J].中国皮肤性病学杂志,2018,32(11):1325-1330. [10] Kurklinsky S, Palmer SC, Arroliga MJ, et al.Neuro-modulation in postherpetic neuralgia: Case reports andreview of the literature[J].Pain Med, 2018,19(6):1237-1244. [11] Wang Y,Qi J,Cao H,et al.Immune responses to varicella-zoster virus glycoprotein E formulated with poly(lactic-co-glycolic Acid)nanoparticles and nucleic acid adjuvants in mice[J].Virol Sin,2021, 36(1): 122-132. [12] Zeng WB,Zhang F, Cheng S, et al.Concerns on vaccine against varicella caused by varicella-zoster virus infection[J].Virol Sin,2021, 36(1): 159-162. [13] Bricout H, Torcel P L, Lecomte C, et al.Determinants of shingles vaccine acceptance in the United Kingdom[J].PLoS One, 2019, 14(8): e220-e230. [14] Curran D, Patterson B, Varghese L, et al.Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States[J].Vaccine, 2018, 36(33):5037-5045. [15] Maltz F.Shingrix: A new herpes zoster vaccine[J].P T, 2019, 44(7): 406-433. [16] 席艳君,王叶子,吴晓冰,等.区域医联体内≥50 岁医务人员带状疱疹疫苗接种意愿及影响因素分析[J].社区医学杂志,2019,17(23):1468-1472. [17] Lam AC,Chan MY,Chou HY,et al.A cross-sectional study of the knowledge,attitude,and practice of patients aged 50 years or above towards herpes zoster in an out-patient setting[J].Hong Kong Med J,2017,23(4):365-573. [18] 仇静,孙晓冬,胡家瑜,等. 2020年5—6月上海市50岁成人带状疱疹疫苗接种意愿调查[J].中国疫苗和免疫,2021,27(3):307-310,327. |